Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13577011 | 0.82 | ALOX5 (0.47) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL13577129 | 0.82 | ALOX5 (0.47) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL13577006 | 0.82 | ALOX5 (0.47) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL13577130 | 0.82 | ALOX5 (0.47) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL18703108 | 0.81 | FFAR1 (0.51) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL4232206 | 0.78 | ALDH1A1 (0.46) | BRD4TDP1LMNASMN1; SMN2 | |
| SCHEMBL6904351 | 0.78 | FFAR1 (0.61) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL11250901 | 0.77 | ALOX5 (0.54) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL8497028 | 0.77 | IGLV6-57 (0.51) | IGLV6-57ALOX5FFAR1KCNH2SCN3A | |
| SCHEMBL10188241 | 0.76 | MAOB (0.53) | IGLV6-57ALOX5FFAR1KCNH2SCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-9040693-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040693-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | IGLV6-57 4878/4885ALOX5 1948/4885FFAR1 2378/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | IGLV6-57 4878/4885ALOX5 1948/4885FFAR1 2378/4885 |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | SHBG, CYP19A1, NR5A1 | IGLV6-57 1676/4885ALOX5 51/4885FFAR1 424/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | IGLV6-57 4878/4885ALOX5 1948/4885FFAR1 2378/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | IGLV6-57 4878/4885ALOX5 1948/4885FFAR1 2378/4885 |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | IGLV6-57 4878/4885ALOX5 1948/4885FFAR1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.